Earnings Preview: Abbott Laboratories and Johnson & Johnson
Abbott Laboratories and Johnson & Johnson are slated to report second quarter earnings this week. Here's what you need to know.
Is This Johnson & Johnson's Worst Nightmare?
Some of Johnson & Johnson's top-performing drugs could soon see a major dip in sales. Here's why.
3 Reasons to Buy Medivation Inc.
Medivation is mid-cap biopharma that looks to have a promising future based on the commercial performance of its prostate cancer drug. Here's what you need to know.
Roche Holding Ltd Is Betting Billions on This New Blockbuster
Roche's move to pay as much as $2 billion for Seragon is a major vote of confidence for an unproven therapy approach
Biotech 101: Off-Label Prescriptions
Investors can learn something from Medivation, GlaxoSmithKline, Amarin and AstraZeneca.